On January 27, Gelonghui reported that SH PHARMA (601607.SH) announced its intention to participate as one of the limited partners in the establishment of a merger and acquisition Fund, with total fundraising expected to reach 5.01 billion yuan, of which SH PHARMA will contribute 1 billion yuan from its own funds. The targeted Fund will focus on the overall development strategy of the Shanghai Biomedical industry, linking Global resources and serving Shanghai's functional positioning. It aims to promote Shanghai's capability to attract and integrate both Global and domestic Biomedical industry innovation resources, collaborate with key areas of Shanghai's Biomedical industry, focus on sub-sectors that are crucial for Shanghai's Biomedical development, and push Shanghai to become a high ground for Biomedical research, economic growth, and industrialization. This will enhance the role of the Industry Chain in leading, driving, and connecting, while also aiming to provide good investment returns for all partners by investing in accordance with applicable laws and the terms of this agreement.
Clear
All
Quotes
News
Learn
Help
All
US
HK
CN
SG
AU
JP
All
News
Announcements
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
上海医药(601607.SH):拟出资10亿元参设并购基金
SH PHARMA (601607.SH): plans to invest 1 billion yuan to establish a merger and acquisition Fund.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Like
Views 325
Write a comment
Statement
This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report